| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;104:181.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Platelet Reactivity Characterized Prospectively
A Determinant of Outcome 90 Days After Percutaneous Coronary Intervention
From the Department of Medicine, The University of Vermont College of Medicine, Burlington, Vt.
Correspondence to Samer S. Kabbani, MD, Cardiology Unit, Fletcher Allen Health Care, McClure 1, Burlington, VT 05401. E-mail samerk{at}pol.net
Background—— Platelet activation is pivotal in the pathogenesis of complications after percutaneous coronary interventions (PCI). We previously reported substantial interindividual variability in activation of glycoprotein (GP) IIb/IIIa in response to a low concentration of ADP. We assessed GP IIb/IIIa activation prospectively to determine whether this could differentiate patients at low risk from those at high risk for complications early and late after PCI.
Methods and Results—— A total of 112 patients undergoing PCI were studied. Platelet reactivity was determined with the use of flow cytometry. Patients were classified into high and low platelet reactivity groups on the basis of extent of activation of GP IIb/IIIa in response to 0.2 µmol/L ADP. The median value was used for differentiation. The incidence during 90-day follow-up interval of a composite end point (myocardial infarction, urgent revascularization, or repeat revascularization) was determined in each group. Follow up was completed in all 112 patients. The 2 groups were similar with respect to diverse clinical characteristics. Nevertheless, the incidence of the composite end point occurred in 26.8% of the high and 7.1% in the low platelet reactivity group (P=0.01). The difference in the composite end point was most striking during the 30- to 90-day interval after PCI (16.7% versus 1.9%; P=0.02). Repeat revascularization was more frequent in those with increased platelet reactivity (17.9% versus with 3.6%, P=0.029).
Conclusions—— Prospective assessment of platelet GP IIb/IIIa activation permits stratification of patients into low- and high-risk groups with respect to adverse events after PCI.
Key Words: platelets • angioplasty • complications • restenosis
This article has been cited by other articles:
 |
|
 |
|
  S. Momi, E. Falcinelli, S. Giannini, L. Ruggeri, L. Cecchetti, T. Corazzi, C. Libert, and P. Gresele Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo J. Exp. Med., October 26, 2009; 206(11): 2365 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events Psychosom Med, September 1, 2009; 71(7): 741 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and H. S. Taatjes-Sommer Augmentation of Megakaryocyte Expression of Fc{gamma}RIIa by Interferon {gamma} Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1138 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider, R. M. Hardison, N. Lopes, B. E. Sobel, M. M. Brooks, and the Pro-Thrombosis Ancillary Study Group Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes: A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy Diabetes Care, May 1, 2009; 32(5): 944 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Reid, P. H. Seidelin, W. J. Kop, M. J. Irvine, B. H. Strauss, R. P. Nolan, H. K. Lau, and E. L. Yeo Mental Stress-Induced Platelet Activation Among Patients With Coronary Artery Disease Psychosom Med, May 1, 2009; 71(4): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bednar, P. Osmancik, T. Vanek, H. Mocikova, M. Jares, Z. Straka, and P. Widimsky Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, S. Tognazzo, G. Cicchitelli, L. Catozzi, P. Malagutti, M. Anselmi, C. Vassanelli, et al. Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention: Insights Into the STRATEGY Study J. Am. Coll. Cardiol., November 9, 2006; (2006) j.jacc.2005.12.085v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Harding, J N Din, J Sarma, D H Josephs, K A A Fox, and D E Newby Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin Heart, November 1, 2006; 92(11): 1635 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yngen, A. Norhammar, P. Hjemdahl, and N H. Wallen Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty Diabetes and Vascular Disease Research, May 1, 2006; 3(1): 52 - 56. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease Diabetes, March 1, 2006; 55(3): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, K. P. Bliden, K. Guyer, P. W. Cho, K. A. Zaman, R. P. Kreutz, A. K. Bassi, and U. S. Tantry Platelet Reactivity in Patients and Recurrent Events Post-Stenting: Results of the PREPARE POST-STENTING Study J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1820 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Schneider On Defining Aspirin Resistance J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Yee, C. W. Sun, A. L. Bergeron, J.-f. Dong, and P. F. Bray Aggregometry detects platelet hyperreactivity in healthy individuals Blood, October 15, 2005; 106(8): 2723 - 2729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Inami, S. Nomura, T. Kajiura, K. Yamada, H. Nakamori, N. Takahashi, N. Tsuda, S. Fukuhara, and T. Iwasaka Significance of {alpha}IIb{beta}3 in Subacute Stent ThrombosisAfter Percutaneous Coronary Intervention Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 455 - 459. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment Diabetes, August 1, 2005; 54(8): 2430 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Horvath, C. Y. J. Lu, E. Robert, G. F. Pierce, R. Greene, B. A. Sosnowski, and J. Doukas Improvement of myocardial contractility in a porcine model of chronic ischemia using a combined transmyocardial revascularization and gene therapy approach J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mikkelsson, M. Perola, and P. J. Karhunen Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125. [Abstract] [PDF]
|
|
|
|
|
|
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Yip, S.-S. Chen, J. S. Liu, H.-W. Chang, Y.-F. Kao, M.-Y. Lan, Y.-Y. Chang, S.-L. Lai, W.-H. Chen, and M.-C. Chen Serial Changes in Platelet Activation in Patients After Ischemic Stroke: Role of Pharmacodynamic Modulation Stroke, July 1, 2004; 35(7): 1683 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aggarwal, D. A. Whitaker, J. M. Rimmer, R. J. Solomon, F. J. Gennari, B. E. Sobel, and D. J. Schneider Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1559 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Scott, A. J. Ippolito, and I. B. Krukenkamp Damage to Pulmonary Artery Catheter During Transmyocardial Laser Revascularization Anesth. Analg., March 1, 2004; 98(3): 614 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsiara, M. Elisaf, I. A. Jagroop, and D. P. Mikhailidis Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity? Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 177 - 190. [Abstract] [PDF]
|
|